AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Acurx Pharmaceuticals, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01184DNK2
1.14▼ 0.00 (-0.44%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.14
Day's Range
1.12 – 1.14
52-Week Range
1.07 – 7.55
Volume
21.8K
Avg Volume
84.9K
Share Statistics
Shares Outstanding
Employees
4
Exchange
XNAS
Listed
2021-06-25
Share count as of August 13, 2026

Acurx Pharmaceuticals, Inc. Common Stock (ACXP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Acurx Pharmaceuticals, Inc. Common Stock (ACXP)
What is Acurx Pharmaceuticals, Inc. Common Stock's Market Cap?
Acurx Pharmaceuticals, Inc. Common Stock's Market Cap is $6.0M, based on as-reported figures from SEC (XBRL) filings.
What is Acurx Pharmaceuticals, Inc. Common Stock's Enterprise Value?
Acurx Pharmaceuticals, Inc. Common Stock's Enterprise Value is -$4.7M, based on as-reported figures from SEC (XBRL) filings.
What is Acurx Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Acurx Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$7.5M, based on as-reported figures from SEC (XBRL) filings.
What is Acurx Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Acurx Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -1.42, based on as-reported figures from SEC (XBRL) filings.
What is Acurx Pharmaceuticals, Inc. Common Stock's Net Debt?
Acurx Pharmaceuticals, Inc. Common Stock's Net Debt is -$10.7M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ACXPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
OPERATING EXPENSES
Research and Development
General and Administrative
TOTAL OPERATING EXPENSES
OPERATING LOSS
OTHER INCOME
Interest Income
NET LOSS
Basic net loss per common share
Diluted net loss per common share